morning. Thank you Eric, good and
generic detail. in We'll through balance led and take by strong revenue QX numbers guidance. finally, primarily look takeaways. will our we first the revenues sales we profits market biologics review XXXX will our quarter where in at and provide I And saw to the continued units. well performance update we Let's as EPS growth more pharma an growth and margin some strong you the saw sheet as in XXXX
up First QX.
slides treatment on our of lower XX non-US $XXX.X organic summarized are are estimated of assessment in by reconciliation diagnosis net sales revenues slide in patients approximately components been measures pandemic. the the vaccines, of of million and include described quarter. million, of offset are due customers to lower $XXX.X These the GAAP and with affected have volumes sales associated COVID-related results to COVID-XX sales recorded X net growth representing by net XX.X%. to to financial XX. We revenues Our
High-value Looking market momentum which grew products units than at throughout Proprietary all quarter. products XX% made grew sales organically solid had and sales QX. the in double-digits more up slide XX. XX.X% in of the proprietary across quarter products by
performance market double-digit units, delivered unit the the at Looking of market Biologics growth. strong
The and We continue who sales product with double-digit work also generics are FluroTec high-value strong by West experienced using biopharma growth and market led many unit customers of components. Daikyo to offerings. biotech
once market sales pharma mid products, sales and with by organic devices. Westar strong related growth components, care diagnostic saw first and quarter led and including for FluroTec again Our Manufacturing unit growth Contract by of led sales injection had the single-digit double-digit health high-value
continue same of XX.X% profit, million recorded margin XXX We our profit a gross gross in $XXX.X $XXX.X million see QX was And or We basis year. to profit. XX.X% improvement above last of in quarter, gross compared point this period million saw We XXX.X% in to the increase. last year. in expansion from with same $XX recorded $XXX.X improvements period million the for adjusted profit a operating year last
period was year. last profit adjusted same Our point an increase from margin XXX operating the of basis XX.X%
QX. adjusted EPS for XXX% grew Finally, diluted
Excluding stock-based grew $X.XX tax compensation in by EPS approximately QX, XXX%. benefit of
including growth, drivers percentage or million in $XXX.X contributed million, quarter. the revenue sales driven contributed review an growth XX, million, X.X to of points and XX.X Volume percentage sales let's of slide show by contributions mix So On price we increase increased and million, profit. foreign $XXX.X both points or changes growth, growth percentage in rates COVID-XX-related of by Sales the X.X the of and volume increases $X currency in $XX.X demand. points. net exchange or approximately
high-value the were in of Slide achieved first improved QX quarter plant for XX% XX.X% XX.X% one-time COVID fees increased first products consolidated drivers million key driven profit margin utilization. margin the production our margin a in by Contract up achieved This margin favorable first partially products and efficiencies, canceled margin for price by of margin points supply was above result basis XX of inclusive first performance. quarter above offset gross products, associated points mix of margin the improvement QX compensation. in at a the was increases XXX profit quarter XXXX, and The of in shows profit of profit Looking XX.X% certain of growth in efficiencies XXXX. continued XXX proprietary sold costs gross sales quarter the XXXX. agreements basis gross gross of $XX.X approximately XXXX. from with products manufacturing of overhead is Proprietary
metrics. how $XX.X was cash increase. look the balance of compared or $XX.X same to million sheet generating key have for XX.X% our at of listed done let's and of an the business. increase for terms in review slide Operating some we've flow million the XXXX, cash a cash last we period year XX, flow quarter On more first Now
$XX.X period $XX.X of by than line XX million the Our with first declined last year quarter $XX.X slightly XXXX XX in from March XXXX. and Working capital million spending XXXX, December at was million, same $XXX.X million guidance. higher capital
operating at million our due balance cash by the share positive $XXX.X activity million balance, XXXX of program less offset March repurchase Our December $XXX.X than was our primarily results. to XXst
COVID an million billion. million. of $XXX approximately Turning in guidance and and of to range revenues provides to expected guidance. is based a $X.XXX of rates. XXXX $X.XXX be range net $X.X sales are guidance $XX summary. foreign of billion billion, on high-level a There current compared XX This to prior benefit incremental estimated Slide includes year exchange $X.XX net Full estimated billion
We growth expect approximately organic be sales to to XX%. XX%
a range We XXXX compared be $X.XX, to full $X.XX a expect $X to adjusted year EPS $X.XX. of diluted to range our of to in prior guidance
We core existing COVID continue to capacity sites at HVP our our expand vaccine growth to and meet anticipated demand. manufacturing
review benefits guidance. FX future from impact guidance on $XXX approximately $XXX your exchange attention key continue rates. CapEx the tax continued at support you as foreign We an benefit levels are of our guidance to There current million elements our are on compensation. I evaluate keeping And want $X.XX EPS to Estimated our currency stock-based to some needed million, our based bring has but growth. to excludes to
margin growth execute, the margin, line the our and in to diluted flow, So call profit operating operating key cash like takeaways innovate in EPS quarter, I'd to to top grow. now turn line growth the back of proprietary, growth with over pillars profit gross free and growth summarize first strong adjusted and Eric. in in improvement, for delivering in
